NASDAQ:MRUSMerus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Merus NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.35 -0.31 (-2.27 %) (As of 07/14/2020 11:24 AM ET) Add Compare Share Today's Range$13.35Now: $13.35▼$13.6750-Day Range$13.65MA: $15.26▼$16.6552-Week Range$10.19Now: $13.35▼$20.95Volume280 shsAverage Volume77,234 shsMarket Capitalization$387.68 millionP/E RatioN/ADividend YieldN/ABeta0.77 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.67, Merus has a potential upside of 54.8% from its current price of $13.35.Amount of Analyst CoverageMerus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesMerus has received 267 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMerus has received 266 “underperform” votes. (Add your “underperform” vote.)Community SentimentMerus has received 50.09% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote “Outperform” if you believe MRUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have bought 197,376.46% more of their company's stock than they have sold. Specifically, they have bought $21,801,401.00 in company stock and sold $11,040.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Merus is held by insiders.Percentage Held by Institutions62.00% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($2.29) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRUS Previous Symbol CUSIPN/A CIK1651311 Webwww.merus.nl Phone31-0-30-253-8800Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.13 million Price / Sales12.45 Cash FlowN/A Price / Cash FlowN/A Book Value$5.61 per share Price / Book2.38Profitability EPS (Most Recent Fiscal Year)($2.33) Net Income$-55,150,000.00 Net Margins-225.21% Return on Equity-62.96% Return on Assets-27.54%Miscellaneous Employees98 Outstanding Shares29,040,000Market Cap$387.68 million Next Earnings Date8/17/2020 (Estimated) OptionableNot Optionable NASDAQ:MRUS Rates by TradingView Receive MRUS News and Ratings via Email Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Merus (NASDAQ:MRUS) Frequently Asked Questions How has Merus' stock been impacted by COVID-19 (Coronavirus)? Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRUS stock has decreased by 8.2% and is now trading at $13.35. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Merus? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus. When is Merus' next earnings date? Merus is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020. View our earnings forecast for Merus. How were Merus' earnings last quarter? Merus NV (NASDAQ:MRUS) issued its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.14. The biotechnology company had revenue of $6.30 million for the quarter, compared to analyst estimates of $8.05 million. Merus had a negative return on equity of 62.96% and a negative net margin of 225.21%. View Merus' earnings history. What price target have analysts set for MRUS? 3 analysts have issued 12 month price objectives for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they expect Merus' share price to reach $20.67 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price. View analysts' price targets for Merus. Has Merus been receiving favorable news coverage? Media headlines about MRUS stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merus earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Merus. Are investors shorting Merus? Merus saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 288,300 shares, an increase of 14.1% from the June 15th total of 252,600 shares. Based on an average daily volume of 164,600 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.5% of the company's stock are short sold. View Merus' Current Options Chain. Who are some of Merus' key competitors? Some companies that are related to Merus include Epizyme (EPZM), BELLUS Health (BLUSF), Intra-Cellular Therapies (ITCI), Zymeworks (ZYME), Zogenix (ZGNX), MacroGenics (MGNX), INDIVIOR PLC/S (INVVY), Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX), Passage Bio (ZNTL), Cytokinetics (CYTK), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), Revance Therapeutics (RVNC) and Karyopharm Therapeutics (KPTI). View all competitors. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE). Who are Merus' key executives? Merus' management team includes the following people: Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific AdvisorMs. Jillian Connell, VP of Investor Relations & Corp. CommunicationsMr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52) When did Merus IPO? (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. What is Merus' stock symbol? Merus trades on the NASDAQ under the ticker symbol "MRUS." How do I buy shares of Merus? Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Merus' stock price today? One share of MRUS stock can currently be purchased for approximately $13.35. How big of a company is Merus? Merus has a market capitalization of $387.68 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe. What is Merus' official website? The official website for Merus is www.merus.nl. How can I contact Merus? Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
